Daily Market Research Report

February 24, 2026

Alpha Signal Monitor

Welcome to your daily pre-market briefing. This report provides key insights on market opportunities and analyst perspectives to help identify potential alpha signals.

Today's Coverage: - Gold ETF Outlook: Institutional perspectives on gold-backed ETFs - Stock Ratings: Latest analyst ratings and target prices for our watchlist - IPO Calendar: Upcoming initial public offerings and market debuts

Watchlist Stocks: AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA, AVGO, TSM

This report is generated using advanced AI research capabilities with real-time market data access.

Institutional outlook on physical gold ETFs (GLD, IAU, BAR) — as of February 24, 2026

Trading Idea: Buy Rationale (TL;DR): Multiple top-tier institutions (JPMorgan, UBS, Goldman Sachs, Bank of America, Morgan Stanley, HSBC, Deutsche Bank) are structurally bullish on gold into late‑2026, citing persistent central‑bank accumulation, re‑accelerating ETF demand as real rates drift lower, and policy/geopolitical uncertainty. With forecast bands clustering around ~$4,500–$5,300/oz into 2H26, we favor broad exposure via large, liquid physical ETFs (GLD, IAU, BAR). (jpmorgan.com)

Context for GLD/IAU/BAR: Gold set new highs into February 2026 amid rising tariff/trade and geopolitical risk, a softer dollar, and expectations that real rates will decline. Central‑bank purchases remain a powerful, price‑insensitive bid (JPM projects ~585 tonnes/quarter in 2026; UBS guided to ~1,000t in 2025 and continued official accumulation), while ETF flows have flipped back to net buying since mid‑2024 and strengthened in 2025. As of February 23–24, 2026, spot/futures trade near recent record territory. (jpmorgan.com)

Key Drivers - Official‑sector (central bank) reserve diversification sustaining multi‑year demand. (jpmorgan.com) - Falling/low real yields and a weaker USD improving the carry and FX backdrop for bullion. (ubs.com) - Re‑acceleration of ETF inflows as Western investors return; banks flag renewed net buying. (ubs.com) - Policy/geopolitical uncertainty (tariffs, great‑power tensions) supporting safe‑haven demand. (ft.com) - Banks’ 2026 target clusters ($4.5k–$5.3k) imply supportive risk‑reward for GLD/IAU/BAR versus cash/bonds. (jpmorgan.com)

Risk Considerations - Hawkish surprise from the Fed (slower or fewer cuts), or a rise in real yields, could sap ETF/investor demand. (investing.com) - Central‑bank demand slows or reverses; reserve managers reduce purchases. (ubs.com) - Resolution/de‑escalation of major geopolitical/trade risks reduces safe‑haven bid. (ubs.com) - USD strengthens materially versus peers, weighing on dollar‑priced bullion. (morganstanley.com) - Positioning/demand destruction at elevated prices (e.g., jewelry, retail) leads to sharp pullbacks. (morganstanley.com)

Positioning: Maintain an overweight to physical gold ETFs (GLD, IAU, BAR) through 2H26; add on pullbacks given consensus upside toward ~$5,000/oz and supportive flows from central banks/ETFs. For cost‑sensitive allocations, IAU and BAR offer lower expense ratios; GLD offers superior liquidity. Watch real‑rate trajectory, USD, and official‑sector buying for confirmation. (jpmorgan.com)

Stock Ratings — Street targets and ratings from GS/MS/JPM/BofA/C/Wells for U.S. mega-cap tech (as of 2026-02-24)

Pulled most-recent publicly reported targets/ratings from the six specified U.S. banks. Dates are the latest note we could find per bank for each stock. Targets are shown in USD.

AAPL - Apple Inc.

Broadly positive across the six banks after 2026 refreshes by JPM and Goldman; Wells Fargo’s last widely reported figure is from late 2025.

Consensus View - Rating: Buy, Target Price: $316 - Simple average of listed targets from the six banks.

MSFT - Microsoft Corp.

Mixed 1/29/2026 reset across the Street; GS trimmed to $600 while MS kept an Overweight stance with a $650 PT earlier in January.

Consensus View - Rating: Buy, Target Price: $595 - Simple average of the six listed targets.

GOOGL - Alphabet Inc.

Strong early‑2026 target lifts from GS, JPM, Citi; Wells Fargo upgraded to Overweight with a 2026 target.

Consensus View - Rating: Buy, Target Price: $359 - Simple average of the six listed targets.

AMZN - Amazon.com Inc.

After Amazon’s 2026 capex guide, most banks reduced targets but kept positive ratings; Wells Fargo raised to a Street‑high among these six.

Consensus View - Rating: Buy, Target Price: $285 - Simple average of the six listed targets.

NVDA - NVIDIA Corp.

All six banks positive; BofA and Wells Fargo carry the highest among the six cited here into early 2026.

Consensus View - Rating: Buy, Target Price: $250 - Simple average of listed targets rounds to ~$250.

META - Meta Platforms Inc.

Fresh 2026 target lifts from Goldman, JPM; Wells Fargo nudged higher to mid‑$800s; Citi kept Meta a top pick with an $803 PT last summer.

Consensus View - Rating: Buy, Target Price: $814 - Average of the five listed targets (BofA pending) is ≈$814.

TSLA - Tesla Inc.

Street is split; Morgan Stanley is Neutral/Equal‑Weight with a mid‑$400s PT following Jan 29, 2026 resets. We will supplement with the other banks on request.

Consensus View - Insufficient uniform data from the six banks in this pass.

AVGO - Broadcom Inc.

Street average implies strong double‑digit upside into 2026; specific targets from the six named banks will be added on request.

Consensus View - Needs additional bank‑specific entries to compute.

TSM - Taiwan Semiconductor Manufacturing Co.

Consensus Buy; Goldman recently lifted to a Street‑high among large U.S. banks; BofA also positive.

Consensus View - Rating: Buy, Target Price: $468 - Average of GS and BofA targets shown; more banks pending.

Highlights

• AAPL: GS $330 (Buy, 2026-01-30); JPM $325 (OW, 2026-01-30); MS $315 (OW); consensus ≈$316.
• MSFT: GS $600 (Buy, 2026-01-29); MS $650 (OW, 2026-01-14); JPM $550 (OW); consensus ≈$595.
• GOOGL: GS $375 (Buy); JPM $395 (OW); Citi $390 (Buy); WFC upgrade to Overweight with $387 PT on 2026-02-24.
• AMZN: Post‑capex reset—JPM $265 (OW, 2026-02-06); WFC $305 (OW, 2026-02-06); GS $290 (Buy).
• NVDA: Broad strength—BofA $275 (Buy, 2026-01-06); WFC $265 (OW); GS/MS/JPM $250.
• META: GS $835; JPM $825; WFC $856; Citi $803; consensus of listed ≈$814.
• TSLA: MS Equal Weight $415 on 2026-01-29; other banks pending.
• TSM: GS $466 (Buy, last month); BofA $470 (Buy, 2026-01-15).

Notes: Targets/ratings above reflect the latest publicly available items as of 2026-02-24 with accessible links. Some banks’ primary research is paywalled; where direct notes weren’t public, we used reputable secondary sources (MarketBeat, Investing.com, Barron’s, etc.). Happy to fill in the remaining gaps (TSLA, AVGO, TSM for MS/JPM/C/WFC) or compute weighted consensuses on request.

IPO Calendar

Timeframe: February 24, 2026 to March 24, 2026

As of February 24, 2026, the near-term U.S. IPO calendar is light but active around biotech: Generate Biomedicines has set terms for a late‑February pricing window, and Salspera has set terms without a final date. Seasonally, late‑February/early‑March is often quiet as issuers finalize year‑end audits, and recent volatility (e.g., Clear Street’s day‑of postponement) has kept windows fragile. Index providers are also proposing “fast‑entry” rules to add large-cap IPOs to major benchmarks more quickly, a potential tailwind for blockbusters expected later in 2026. (renaissancecapital.com)

Generate Biomedicines, Inc. (GENB)

• Expected listing date: February 26, 2026 (expected pricing; trade date may follow)
• Price range: $15.00 – $17.00 (25.0M shares)
• Shares offered: 25,000,000 primary shares (base deal; standard 30‑day option may apply)
• Exchange: Nasdaq
• Lead underwriters: Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, Cantor Fitzgerald
• Business summary: Clinical‑stage “generative biology” company using an AI-enabled platform to design protein therapeutics. Lead program GB‑0895 (long‑acting anti‑TSLP mAb) is in pivotal Phase 3 trials for severe asthma; proceeds earmarked for Phase 3 execution, COPD study, and platform/pipeline advancement. (renaissancecapital.com)
• Notes: Terms filed February 23, 2026; expected to price the week of February 23 with marketing indicating a February 26 pricing target; timing subject to market conditions. Financials and terms from SEC S‑1/S‑1A and Renaissance Capital profile/news. (streetinsider.com)
• Sources: Renaissance Capital – Generate Biomedicines profile and terms, SEC EDGAR – S‑1/S‑1A (filed Feb 4 and Feb 23, 2026), Bloomberg Law – expected pricing timing (Feb 23, 2026)

Salspera, Inc. (TKVA)

• Price range: $14.00 – $16.00 (5.7M shares)
• Shares offered: 5,700,000 shares (base deal)
• Exchange: Nasdaq
• Lead underwriters: Kingswood Capital Markets (sole bookrunner)
• Business summary: Clinical‑stage immuno‑oncology company developing “live biopharmaceuticals” (engineered bacteria) to stimulate antitumor immune responses. Lead candidate Saltikva (attenuated Salmonella Typhimurium expressing IL‑2) is advancing toward pivotal studies in metastatic pancreatic cancer. (renaissancecapital.com)
• Notes: Company set terms on February 23, 2026; no firm pricing date disclosed as of February 24, 2026. Deal size and timing may change or be withdrawn depending on market conditions. (renaissancecapital.com)
• Sources: Renaissance Capital – Salspera profile and terms (Feb 23, 2026), Reuters via MarketScreener/ZoneBourse – price range mention (Feb 23, 2026)

MiniMed Group, Inc. (Medtronic diabetes carve‑out) (MMED)

• Exchange: Nasdaq
• Lead underwriters: Goldman Sachs, BofA Securities, Citigroup, Morgan Stanley
• Business summary: Carve‑out of Medtronic’s diabetes business (insulin pumps, CGMs, software/consumables) intended to list as a majority‑owned subsidiary at IPO with a subsequent split‑off contemplated. Proceeds expected to fund the standalone business and support growth in automated insulin delivery and sensing. (renaissancecapital.com)
• Notes: Filed a Form S‑1 on December 19, 2025; terms and launch timing not yet set. Could launch a roadshow as audited financials finalize; inclusion here reflects a credible near‑term pipeline candidate rather than a scheduled offering. (hmenews.com)
• Sources: Renaissance Capital – MiniMed filing note (Dec 19, 2025), Investing.com (Reuters) – MiniMed IPO filing and underwriters, HME News – Medtronic announcement of MiniMed S‑1 filing

Motive Technologies, Inc. (MTVE)

• Exchange: NYSE
• Lead underwriters: J.P. Morgan, Citigroup, Barclays, Jefferies, (plus additional joint bookrunners per company release)
• Business summary: AI‑powered platform for fleet and physical‑operations management (safety, compliance, spend, equipment/asset tracking) serving logistics, construction, energy and other sectors. Filed to list on the NYSE under “MTVE.” (sec.gov)
• Notes: Public S‑1 filed December 23, 2025; no terms or launch date as of February 24, 2026. Could move quickly if markets stabilize; timing uncertain. (sec.gov)
• Sources: SEC EDGAR – Motive S‑1 (Dec 23, 2025), Motive press release – proposed NYSE:MTVE and underwriters

Grayscale Investments, LLC (GRAY)

• Exchange: NYSE
• Lead underwriters: Morgan Stanley, BofA Securities, Jefferies, Cantor Fitzgerald
• Business summary: Crypto‑asset manager (ETFs and private funds across digital assets) pursuing a traditional IPO after confidential and then public S‑1 filings in 2025; would be one of the largest crypto‑native asset managers to list in the U.S. Timing remains subject to SEC review and market conditions. (globenewswire.com)
• Notes: Public S‑1 announced November 13, 2025; no terms or date as of February 24, 2026. Included as an “expected” offering given an active filing and named bookrunners, but the deal may slip beyond the coming month. (globenewswire.com)
• Sources: Company press release – public S‑1 and proposed ticker GRAY (Nov 13, 2025), CoinDesk – filing context and market backdrop

Dates and terms can change quickly; offerings may be postponed or withdrawn at short notice. Where dates are shown as “expected,” they reflect current marketing/filing indications as of February 24, 2026, and not exchange‑confirmed listings. Size and underwriter lineups are based on the latest public filings or issuer/underwriter announcements and may update during bookbuilding. Clear Street’s recent postponement underscores the fragile window; monitor late‑breaking calendar changes. (ft.com)

Sources

• Stock Ratings: https://finance.yahoo.com/news/apple-stock-target-raised-bofa-135505743.html, https://finance.yahoo.com/news/nvidia-stock-rises-wells-fargo-132336478.html, https://it.investing.com/news/analyst-ratings/goldman-sachs-conferma-il-rating-buy-su-amazon-e-alza-il-target-di-prezzo-93CH-3069289, https://m.it.investing.com/news/analyst-ratings/goldman-sachs-alza-il-target-di-prezzo-delle-azioni-meta-platforms-a-835-da-815-93CH-3194017?ampMode=1, https://www.barrons.com/articles/tsmc-stock-buy-goldman-sachs-0701f156, https://www.ebc.com/forex/is-avgo-a-buy-in-2025-broadcom-stock-forecast-and-analysis, https://www.gurufocus.com/news/3152412/aapl-wells-fargo-raises-price-target-to-290-maintains-overweight-rating-aapl-stock-news, https://www.gurufocus.com/news/4109066/googl-goldman-sachs-maintains-buy-rating-raises-price-target-googl-stock-news, https://www.gurufocus.com/news/8643693/wells-fargo-raises-price-target-for-meta-stock-to-856-meta-stock-news, https://www.investing.com/equities/taiwan-semicond.manufacturing-co-consensus-estimates, https://www.investing.com/news/analyst-ratings/bofa-securities-reaffirms-nvidia-stock-buy-rating-with-275-price-target-93CH-4431532, https://www.investing.com/news/analyst-ratings/goldman-sachs-raises-nvidia-stock-price-target-to-250-on-ai-outlook-93CH-4369369, https://www.investing.com/news/analyst-ratings/jpmorgan-raises-meta-stock-price-target-to-825-on-strong-revenue-outlook-93CH-4473043, https://www.investing.com/news/analyst-ratings/meta-platforms-stock-price-target-lowered-to-750-by-morgan-stanley-93CH-4402248, https://www.investing.com/news/analyst-ratings/morgan-stanley-reiterates-overweight-rating-on-microsoft-stock-at-650-93CH-4446158, https://www.investopedia.com/meta-called-a-top-pick-by-citi-analysts-on-digital-ad-strength-11760351, https://www.investopedia.com/nvidia-stock-gets-price-target-bump-from-citi-on-sovereign-ai-demand-surge-11767497, https://www.investors.com/news/technology/google-stock-wells-fargo-upgrades-ai-winner/, https://www.marketbeat.com/instant-alerts/amazoncom-nasdaqamzn-given-new-28600-price-target-at-bank-of-america-2026-01-27/, https://www.marketbeat.com/instant-alerts/citigroup-issues-positive-forecast-for-alphabet-nasdaqgoogl-stock-price-2026-02-06/, https://www.marketbeat.com/instant-alerts/microsofts-msft-buy-rating-reiterated-at-the-goldman-sachs-group-2026-01-29/, https://www.marketbeat.com/instant-alerts/morgan-stanley-forecasts-strong-price-appreciation-for-nvidia-nasdaqnvda-stock-2025-12-01/, https://www.marketbeat.com/instant-alerts/wells-fargo-company-increases-amazoncom-nasdaqamzn-price-target-to-30500-2026-02-06/, https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/, https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/, https://www.marketbeat.com/stocks/NASDAQ/GOOG/forecast/, https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/, https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/, https://www.marketwatch.com/story/how-amazons-underappreciated-ai-potential-could-drive-the-stock-50-higher-1a4aa628, https://www.tipranks.com/news/is-broadcom-stock-a-buy-for-2026-analysts-predict-over-30-upside, https://www.tipranks.com/news/the-fly/amazon-com-price-target-lowered-to-265-from-305-at-jpmorgan-thefly, https://www.tipranks.com/news/the-fly/nvidia-price-target-raised-to-250-from-215-at-jpmorgan-thefly
• IPO Calendar: https://www.ft.com/content/e0c71b94-b761-496c-a251-f106cbb9353a?utm_source=openai, https://www.globenewswire.com/news-release/2025/11/13/3187426/0/en/Grayscale-Investments-Announces-Public-Filing-of-Registration-Statement-for-Proposed-Initial-Public-Offering.html?utm_source=openai, https://www.hmenews.com/article/medtronic-starts-ipo-process-for-minimed?utm_source=openai, https://www.renaissancecapital.com/IPO-Center/News/115717/Medtronic-diabetes-business-carve-out-MiniMed-Group-files-for-a-%24100-millio?utm_source=openai, https://www.renaissancecapital.com/IPO-Center/News/117178/Asthma-focused-AI-biotech-Generate-Biomedicines-sets-terms-for-%24400-million?utm_source=openai, https://www.renaissancecapital.com/IPO-Center/News/117206/Immuno-oncology-biotech-Salspera-sets-terms-for-%2485-million-IPO?utm_source=openai, https://www.renaissancecapital.com/Profile/GENB/Generate-Biomedicines/IPO, https://www.renaissancecapital.com/Profile/TKVA/Salspera/IPO, https://www.sec.gov/Archives/edgar/data/1646681/000162828025058773/motive-sx1.htm?utm_source=openai, https://www.streetinsider.com/SEC%2BFilings/Form%2BS-1A%2BGenerate%2BBiomedicines%2C/26038907.html?utm_source=openai

Disclaimer

This research report is for informational purposes only and does not constitute investment advice. All information is sourced from publicly available data and should be verified independently. Past performance does not guarantee future results.

Generated on: 2026-02-24 at 11:27 UTC
Source: Alpha Signal Monitor - Automated Research System
Contact: For questions about this report, please contact your Alpha Signal Monitor administrator.

Powered by Alpha Signal Monitor | Market Intelligence Through AI